Abstract: A modified collagen hybridizing peptide (CHP) may include one or more binding partners crosslinked to a CHIP. The CHP has a sequence represented by Formula (I): (Gly-X-Y)a-b, wherein Gly is glycine, at least one of X and Y is proline, modified proline and/or hydroxy proline, and a is 3 and b is 20. The one or more binding partners is selected from the group consisting of integrin sites, integrin binding sites, crosslinking sites, von Willebrand Factor (VWF) discoidin domain receptor (DDR) 1, DDR 2, SPARC binding peptides, fibronectin binding peptides, engineered integrin binding peptides, matrix metalloproteinase (MMP) cleavage sites. Cathepsin K (CATK) sites, and osteoclast-associated receptors (OSCAR).

Abstract: The present disclosure provides methods for determining collagen content using collagen hybridizing peptides. The present disclosure provides methods for quantifying an amount of disrupted collagen (e.g., collagen with disrupted triple helicity) and/or total collagen. The present disclosure provides methods for quantifying an amount of disrupted collagen (e.g., collagen with disrupted triple helicity) as a portion of total collagen.